Nothing Special   »   [go: up one dir, main page]

AU2002223492A1 - Use of malaria parasite anion channel blockers for treating malaria - Google Patents

Use of malaria parasite anion channel blockers for treating malaria

Info

Publication number
AU2002223492A1
AU2002223492A1 AU2002223492A AU2349202A AU2002223492A1 AU 2002223492 A1 AU2002223492 A1 AU 2002223492A1 AU 2002223492 A AU2002223492 A AU 2002223492A AU 2349202 A AU2349202 A AU 2349202A AU 2002223492 A1 AU2002223492 A1 AU 2002223492A1
Authority
AU
Australia
Prior art keywords
malaria
channel blockers
anion channel
treating
parasite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002223492A
Inventor
Palle Christophersen
Bjarne H. Dahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of AU2002223492A1 publication Critical patent/AU2002223492A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002223492A 2000-11-14 2001-11-12 Use of malaria parasite anion channel blockers for treating malaria Abandoned AU2002223492A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200001705 2000-11-14
DKPA200001705 2000-11-14
US25246700P 2000-11-22 2000-11-22
US60252467 2000-11-22
PCT/DK2001/000745 WO2002039987A2 (en) 2000-11-14 2001-11-12 Use of malaria parasite anion channel blockers for treating malaria

Publications (1)

Publication Number Publication Date
AU2002223492A1 true AU2002223492A1 (en) 2002-05-27

Family

ID=26068909

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002223492A Abandoned AU2002223492A1 (en) 2000-11-14 2001-11-12 Use of malaria parasite anion channel blockers for treating malaria

Country Status (2)

Country Link
AU (1) AU2002223492A1 (en)
WO (1) WO2002039987A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
ES2201909B1 (en) * 2002-06-06 2005-02-16 Universitat De Valencia Estudi General. USE OF N- (2-CHLOROPIRIDIN-4-IL) -N'-PHENYLURES AND N- (3-NITROPHENYL) -N'-FLUORATED PHENYLURES AS PROMOTERS OF FRUIT GROWTH IN CROPS OF DELICIOUS ACTINIDIA.
DE60328202D1 (en) * 2002-09-05 2009-08-13 Neurosearch As DIARYL HARVEST DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS
AU2003258491A1 (en) * 2002-09-05 2004-03-29 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
ATE431335T1 (en) 2002-11-21 2009-05-15 Neurosearch As DIARYLUREIDO DERIVATIVES AND THEIR MEDICAL USE
WO2004111017A1 (en) * 2003-06-17 2004-12-23 Neurosearch A/S Diphenylurea derivatives and their use as chloride channel blockers
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
CA2559038C (en) 2004-03-23 2013-09-10 Arena Pharmaceuticals, Inc. Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl) phenyl] ureas and intermediates thereof
DE102004046492A1 (en) * 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
PE20061130A1 (en) 2004-11-19 2007-01-05 Arena Pharm Inc 3-PHENYL-PIRAZOLE DERIVATIVES AS MODULATORS OF THE SEROTONIN 5-HT2A RECEPTOR
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
CN101365690A (en) 2005-10-12 2009-02-11 沃泰克斯药物股份有限公司 Biphenyl derivatives as modulators of voltage gated ion channels
BRPI0708034A2 (en) 2006-02-10 2011-05-17 Transtech Pharma Inc benzazole derivatives, compositions and methods of use as aurora kinase inhibitors
JP5389642B2 (en) 2006-05-18 2014-01-15 アリーナ ファーマシューティカルズ， インコーポレイテッド 3-pyrazolyl-benzamido-4-ethers, secondary amines and derivatives thereof as modulators of 5-HT2A serotonin receptors useful for the treatment of disorders associated with 5-HT2A serotonin receptors
NZ571829A (en) 2006-05-18 2011-10-28 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
EP2018371B1 (en) 2006-05-18 2015-03-04 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
TWI415845B (en) 2006-10-03 2013-11-21 Arena Pharm Inc Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US9567327B2 (en) 2007-08-15 2017-02-14 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010011537A1 (en) 2008-07-23 2010-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the plasmodial surface anion channel as antimalarials
JP5449351B2 (en) 2008-07-23 2014-03-19 アリーナ ファーマシューティカルズ， インコーポレイテッド Substituted 1,2,3,4-tetrahydrocyclopenta [b] indol-3-yl) acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
RU2530899C2 (en) * 2008-07-28 2014-10-20 Селлсьютикс Корпорейшн Antimalarial compounds
PL2342205T4 (en) 2008-08-27 2016-12-30 Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
NO2364142T3 (en) 2008-10-28 2018-06-16
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN102884064B (en) 2010-03-03 2016-01-13 艾尼纳制药公司 Prepare the method for S1P1 receptor modulators and crystalline form thereof
DE102012007558A1 (en) * 2012-04-14 2013-10-17 Alf Hammes Use of diarylurea-derivatives for treating the symptoms of anemia, thalassemia, sickle cell anemia and Diamond-Blackfan anemia
WO2015054662A1 (en) 2013-10-10 2015-04-16 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
MX2017008925A (en) 2015-01-06 2017-10-11 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor.
RU2017145976A (en) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Diaryl- and arylheteroarylurea derivatives applicable for the prevention and treatment of behavioral disturbances during the REM phase of sleep
PL3310760T3 (en) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders
AU2016291673A1 (en) 2015-07-15 2018-01-25 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CN110545848A (en) 2017-02-16 2019-12-06 艾尼纳制药公司 Compounds and methods for treating inflammatory bowel disease with extra-intestinal manifestations
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US10370352B2 (en) 2017-09-07 2019-08-06 Eli Lilly And Company Cyclobutyl-imidazolidinone compounds
WO2019047094A1 (en) * 2017-09-07 2019-03-14 Eli Lilly And Company Cyclobutyl-imidazolidinone compounds
WO2020051378A1 (en) 2018-09-06 2020-03-12 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
WO2020079051A1 (en) * 2018-10-16 2020-04-23 Scandion Oncology A/S Compounds for treatment of microbial infection
JP7336133B2 (en) * 2019-08-07 2023-08-31 国立大学法人東北大学 Diphenylurea compound derivative
TW202245800A (en) 2020-02-18 2022-12-01 美商基利科學股份有限公司 Antiviral compounds
TWI794742B (en) 2020-02-18 2023-03-01 美商基利科學股份有限公司 Antiviral compounds
TWI777411B (en) 2020-02-18 2022-09-11 美商基利科學股份有限公司 Antiviral compounds
KR20230170745A (en) 2021-04-16 2023-12-19 길리애드 사이언시즈, 인코포레이티드 Method for producing carbanucleosides using amides
AU2022328698A1 (en) 2021-08-18 2024-02-01 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Also Published As

Publication number Publication date
WO2002039987A2 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
AU2002223492A1 (en) Use of malaria parasite anion channel blockers for treating malaria
AU2001268062A1 (en) Multi-channel optical transceiver
AU2002354608A1 (en) Synchronization among plural browsers
AU2001275511A1 (en) Guide for medical devices
AUPR575401A0 (en) Method of causing sloughing
AU2001286983A1 (en) Method of treatment
AU2002220170A1 (en) Asymmetric orthogonal codes for optical communications
AU2002241670A1 (en) Method for treating glaucoma IB
AU2002361763A1 (en) Method of reducing angiogenesis
AU3396801A (en) Communications apparatus
AU2002305261A1 (en) Fibre channel transceiver
AU2001262177A1 (en) Method of treatment
GB2371731B (en) Method of alignment
AU2002365356A1 (en) Bobbin holder
AU2002304733A1 (en) Amino-aza-cyclohexanes for the treatment of malaria
GB0200803D0 (en) Application guide
AU2002242613A1 (en) Guide groove
AUPQ821600A0 (en) Positioning of communications devices
TW496268U (en) Structure of lacework cutter
AU2002317789A1 (en) Communications device
AUPQ811200A0 (en) Treatment of alopecia
AU2002247839A1 (en) Anti-malarial compounds
AU2002234082A1 (en) Method for treating glaucoma iiib
AU2002226538A1 (en) Method of alignment
AU2002355401A1 (en) Structrural head restraint guide